Thomas J. Sayers
Cancer and Inflammation Program
The Center for Cancer Research
United States of America
Biography
Dr. Thomas Sayers is a senior scientist with Leidos Biomedical Research, Inc. and works in collaboration with the Laboratory of Experimental Immunology in the Cancer and Inflammation Program. Dr. Sayers obtained his Ph.D. in biochemistry from the University of London and performed postdoctoral studies on purification of autoantigens at the Medical Clinic of the University of Tubingen, Germany. He also worked as a laboratory leader in the Department of Immunotherapy at the Sandoz Research Institute, Vienna, Austria, before coming to the NCI.
Research Interest
Cancer Biology, Immunology, Molecular Biology and Biochemistry
Publications
-
Shanker A, Brooks AD, Jacobsen KM, Wine JW, Wiltrout RH, et al. (2009) Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res. 69: 6615-23.
-
Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, et al. (2008) Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst. 100: 649-62.
-
Sayers TJ, Brooks A, Koh C, Ma W, Seki N, et al. (2003) The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood. 102: 303-10.
-
Seki N, Hauakawa Y, Brooks AD, Wine J, Wiltrout RH, et al. (2003) Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res. 63: 207-13.
-
Seki N, Brooks AD, Back TC, Carter CRD, Parsoneault EM, et al. (2002) Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol. 168: 3484-92.
